c 1311 has been researched along with tryptoquivaline in 1 studies
| Studies (c 1311) | Trials (c 1311) | Recent Studies (post-2010) (c 1311) | Studies (tryptoquivaline) | Trials (tryptoquivaline) | Recent Studies (post-2010) (tryptoquivaline) |
|---|---|---|---|---|---|
| 52 | 1 | 23 | 83 | 0 | 28 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Assaraf, YG; Bram, EE; Grimberg, M; Ifergan, I; Lemke, K; Skladanowski, A | 1 |
1 other study(ies) available for c 1311 and tryptoquivaline
| Article | Year |
|---|---|
C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
Topics: Acridines; Aminoacridines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Amplification; Gene Expression Regulation, Neoplastic; Heterozygote; Humans; Indoles; Irinotecan; Mitoxantrone; Neoplasm Proteins; RNA, Messenger; Triazoles | 2007 |